An Open-Label Extension Study of Palovarotene Treatment in FOP
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02279095 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 30, 2014
Last Update Posted : October 26, 2020
|
Sponsor:
Clementia Pharmaceuticals Inc.
Information provided by (Responsible Party):
Ipsen ( Clementia Pharmaceuticals Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability. In this study, the ability of palovarotene to prevent HO formation will be evaluated.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fibrodysplasia Ossificans Progressiva | Drug: Palovarotene dose level 1 Drug: Palovarotene dose level 2 Drug: Palovarotene dose level 3 Drug: Palovarotene dose level 4 | Phase 2 |
The main objective of this Phase 2, multicenter, open-label study is to evaluate the safety and efficacy of different palovarotene dosing regimens in subjects with FOP.
In Part A, all subjects who completed Study PVO-1A-201 and enrolled into the current study received daily treatment with open-label palovarotene for an eligible flare-up at a dose of 10 mg for 14 days, followed by 5 mg for 28 days (or the weight-based equivalent). Part A is completed.
In Part B, subjects with at least 90% skeletal maturity were treated with 5 mg palovarotene on a daily basis (ie, chronically). In the event of an eligible flare-up, all subjects received 20 mg palovarotene daily for 28 days, followed by 10 mg for 56 days (dosing was weight-based in subjects who were skeletally immature). Dosing could be extended if the flare-up was not resolved by Flare-up Day 84 and continued until the flare-up resolved. Dose reduction, as directed by the Investigator, occurred in the event of intolerable side effects. The duration of Part B is up to 24 months.
In Part C, the dosing regimens implemented in Part B will continue except that subjects with less than 90% skeletal maturity will now receive chronic daily administration of palovarotene (5 mg, or the weight-based equivalent). The assessment of HO will occur every 12 months using low-dose, whole body computed tomography (WBCT), excluding head; other efficacy and safety outcomes will be evaluated remotely every 3 months, or monthly during flare-up based treatment. The duration of Part C is 36 months.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 54 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) |
| Actual Study Start Date : | October 27, 2014 |
| Estimated Primary Completion Date : | October 31, 2021 |
| Estimated Study Completion Date : | October 31, 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Fibrodysplasia ossificans progressiva
Idiopathic inflammatory myopathy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Palovarotene dose level 1 (completed)
Subjects received weight-adjusted doses of palovarotene equivalent to 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days for an eligible flare-up (Part A).
|
Drug: Palovarotene dose level 1
Palovarotene was taken orally once daily at approximately the same time each day. |
|
Experimental: Palovarotene dose level 2
Subjects with at least 90% skeletal maturity received 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
|
Drug: Palovarotene dose level 2
Palovarotene will be taken orally once daily at approximately the same time each day. |
|
Experimental: Palovarotene dose level 3
Subjects with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
|
Drug: Palovarotene dose level 3
Palovarotene will be taken orally once daily at approximately the same time each day. |
|
Experimental: Palovarotene dose level 4
All subjects will receive 5 mg palovarotene once daily for up to 36 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Doses are adjusted for weight in skeletally immature subjects
|
Drug: Palovarotene dose level 4
Palovarotene will be taken orally once daily at approximately the same time each day. |
Primary Outcome Measures :
- Change in New HO Volume [ Time Frame: Screening, every 12 months up to 60 months ]Annualized change in new HO volume as assessed by low-dose, WBCT (excluding head).
Secondary Outcome Measures :
- Subjects with New HO [ Time Frame: Baseline, every 12 months up to 60 months ]The proportion of subjects with any new HO.
- Range of Motion [ Time Frame: Baseline, every 6 months up to 60 months ]Change from baseline in range of motion as assessed by the Cumulative Analogue Joint Involvement Scale for FOP (CAJIS).
- FOP-Physical Function Questionnaire [ Time Frame: Baseline, every 6 months up to 60 months ]Change from baseline in physical function using age-appropriate forms of the FOP-Physical Function Questionnaire (PFQ).
- PROMIS Global Health Scale [ Time Frame: Baseline, every 6 months up to 60 months ]Change from baseline in mental and/or physical health function for subjects using age-appropriate forms of the PROMIS Global Health Scale.
- Incidence of Adverse Events [ Time Frame: every month up to 60 months ]Monitor adverse events.
- Pharmacokinetics of Palovarotene [ Time Frame: Pre-dose and 3, 6, 10, and 24 hours post-dose ]Steady-state pharmacokinetics assessed during treatment with 10 and 20 mg palovarotene.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Years to 65 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Completion of Study PVO-1A-202/Part B.
- Written, signed, and dated informed consent and, for subjects who are minors, age-appropriate subject assent (performed according to local regulations).
- Accessible for treatment with palovarotene and follow-up (able and willing to travel to a site for the initial and all follow-up clinic visits).
- Able to undergo low-dose, WBCT scan, excluding head.
- Females of child-bearing potential must have a negative blood or urine pregnancy test (with sensitivity of at least 50 mIU/mL) prior to administration of palovarotene.
- Male and FOCBP subjects must agree to remain abstinent from heterosexual sex during treatment and for 1 month after treatment or, if sexually active, to use two effective methods of birth control during and for 1 month after treatment. Additionally, sexually active FOCBP subjects must already be using two effective methods of birth control 1 month before treatment is to start. Specific risk of the use of retinoids during pregnancy, and the agreement to remain abstinent or use two effective methods of birth control will be clearly defined in the informed consent and the subject or legally authorized representatives.
Exclusion Criteria:
- Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.
- Amylase or lipase >2x above the upper limit of normal or with a history of pancreatitis.
- Elevated aspartate aminotransferase or alanine aminotransferase >2.5x the upper limit of normal.
- Fasting triglycerides >400 mg/dL with or without therapy.
- If currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, herbal preparations containing vitamin A or beta carotene, or fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
- Subjects experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month as defined by the Columbia Suicide Severity Rating Scale (C-SSRS).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02279095
Locations
| United States, California | |
| University of California San Francisco, Division of Endocrinology and Metabolism | |
| San Francisco, California, United States, 94143 | |
| United States, Minnesota | |
| Mayo Clinic, Department of Medicine | |
| Rochester, Minnesota, United States, 55905 | |
| United States, Pennsylvania | |
| University of Pennsylvania, Center for FOP & Related Bone Disorders | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Argentina | |
| Hospital Italiano de Buenos Aires, Department of Pediatrics | |
| Buenos Aires, Argentina | |
| Australia, Queensland | |
| Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) | |
| Woolloongabba, Queensland, Australia, 4102 | |
| France | |
| Hôpital Necker-Enfants Malades, Department of Genetics | |
| Paris, France | |
| United Kingdom | |
| The Royal National Orthopaedic Hospital, Brockley Hill | |
| Stanmore, Middlesex, United Kingdom, HA7 4LP | |
Sponsors and Collaborators
Clementia Pharmaceuticals Inc.
Investigators
| Study Director: | Ipsen Medical Director | Ipsen |
Additional Information:
Publications:
Publications:
| Responsible Party: | Clementia Pharmaceuticals Inc. |
| ClinicalTrials.gov Identifier: | NCT02279095 |
| Other Study ID Numbers: |
PVO-1A-202 2014-002496-28 ( EudraCT Number ) |
| First Posted: | October 30, 2014 Key Record Dates |
| Last Update Posted: | October 26, 2020 |
| Last Verified: | October 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Ipsen ( Clementia Pharmaceuticals Inc. ):
|
Open-label extension study Clinical trial Phase 2 Efficacy and safety Heterotopic ossification Fibrodysplasia Ossificans Progressiva Flare-up Palovarotene |
Retinoic acid receptor agonist Retinoic acid receptor gamma agonist Clementia Myositis Ossificans Progressiva Munchmeyer's Disease FOP |
Additional relevant MeSH terms:
|
Myositis Ossificans Myositis Muscular Diseases Musculoskeletal Diseases |